HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moe, S. M. Articles by Drüeke, T. Search for Related Content PubMed PubMed Citation Articles by Moe, S. M. Articles by Drüeke, T.

Improving Global Outcomes in Mineral and Bone Disorders

Sharon M. Moe^*, and Tilman Drüeke

^* Indiana University School of Medicine and Roudebush VA Medical Center, Indianapolis, Indiana; and INSERM Unit 507 and Division of Nephrology, Hôpital Necker, Université René Descartes, Paris, France

Correspondence: Dr. Sharon M. Moe, Department of Medicine, Indiana University School of Medicine, Roudebush VAMC, 1001 W. 10th Street, OPW 526, Indianapolis, IN 46202. Phone: 317-278-2870; Fax: 317-278-2860; E-mail: smoe{at}iupui.edu

Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease and an important cause of morbidity, decreased quality of life, and extraskeletal calcification that have been associated with increased cardiovascular mortality. Kidney Disease: Improving Global Outcomes (KDIGO)'s Global Mineral and Bone Initiative has sought to update the definition, evaluation, and classification of this mineral and bone disorder; improve standardization of assessment tools; enhance education about these complications; and stimulate research. In addition, this international organization sponsored a Controversies Conference in 2005 to define these complications better. The recommendations from that conference were that (1) the term "renal osteodystrophy" be used exclusively to define alterations in bone morphology that are associated with chronic kidney disease and (2) the term "chronic kidney disease–mineral and bone disorder" (CKD-MBD) can be used to describe the broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism as a result of chronic kidney disease. Chronic kidney disease–related mineral and bone disorders is manifested by an abnormality of any one or a combination of the following: Laboratory (abnormalities of calcium, phosphorus, parathyroid hormone, or vitamin D metabolism), bone (changes in bone turnover, mineralization, volume, linear growth, or strength), and calcification (vascular or other soft tissue calcification). The use of a common, internationally accepted terminology should ease the comparison of studies in this field and eventually improve patient care worldwide.

This article has been cited by other articles:

				S. C. Palmer, J. C. Craig, and G. F. M. Strippoli Taking aim at targets Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1358 - 1361. [Full Text] [PDF]